{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:37:41Z","timestamp":1759178261884,"version":"3.37.3"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Since last year\u2019s report in the European Heart Journal, we have witnessed substantial progress in all aspects of interventional cardiology. Of note, the practice of interventional cardiology took place amidst successive waves of the COVID-19 pandemic, which continues to be a major burden for all healthcare professionals around the globe. In our yearly review, we shall revisit the developments in percutaneous coronary intervention (PCI), structural heart interventions, and adjunctive pharmacotherapy.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehab884","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T04:20:04Z","timestamp":1639455604000},"page":"377-386","source":"Crossref","is-referenced-by-count":6,"title":["The year in cardiovascular medicine 2021: interventional cardiology"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-0112","authenticated-orcid":false,"given":"Javier","family":"Escaned","sequence":"first","affiliation":[{"name":"Complutense University of Madrid Hospital Cl\u00ednico San Carlos IDISCC, , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-384X","authenticated-orcid":false,"given":"Farouc A.","family":"Jaffer","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School Cardiology Division, Department of Medicine, , Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8750-5567","authenticated-orcid":false,"given":"Julinda","family":"Mehilli","sequence":"additional","affiliation":[{"name":"Klinikum der Universitaet M\u00fcnchen, Ludwig-Maximilians-Universitaet and German Centre for Cardiovascular Research (DZHK) Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, , Partner Site Munich Heart Alliance, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai , New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"2022102614581603800_ehab884-B1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jcin.2020.02.015","article-title":"The natural history of nonculprit lesions in STEMI: an FFR substudy of the compare-acute trial","volume":"13","author":"Pir\u00f3th","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jacc.2020.07.034","article-title":"Nonculprit lesion severity and outcome of revascularization in patients with STEMI and multivessel coronary disease","volume":"76","author":"Sheth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102614581603800_ehab884-B3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMoa2104650","article-title":"Multivessel PCI guided by FFR or angiography for myocardial infarction","volume":"385","author":"Puymirat","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102614581603800_ehab884-B4","doi-asserted-by":"crossref","first-page":"e011314","DOI":"10.1161\/CIRCINTERVENTIONS.121.011314","article-title":"Compared outcomes of ST-Elevation myocardial infarction patients with multivessel disease treated with primary percutaneous coronary intervention and preserved fractional flow reserve of non-culprit lesions treated conservatively and of those with low fractional flow reserve managed invasively: insights from the FLOWER MI trial","volume":"14","author":"Denormandie","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jcin.2020.05.024","article-title":"Revascularization deferral of nonculprit stenoses on the basis of fractional flow reserve: 1-year outcomes of 8,579 patients","volume":"13","author":"Cerrato","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B6","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1093\/eurheartj\/ehaa481","article-title":"Management of non-culprit coronary plaques in patients with acute coronary syndrome","volume":"41","author":"Montone","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B7","article-title":"Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study","author":"Banning","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B8","article-title":"Fractional flow reserve\u2013guided PCI as compared with coronary bypass surgery","author":"Fearon","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102614581603800_ehab884-B9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(20)32114-0","article-title":"Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation","volume":"396","author":"Takahashi","year":"2020","journal-title":"Lancet"},{"key":"2022102614581603800_ehab884-B10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jacc.2020.06.066","article-title":"Sex differences in all-cause mortality in the decade following complex coronary revascularization","volume":"76","author":"Hara","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102614581603800_ehab884-B11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2021.04.087","article-title":"Impact of optimal medical therapy on 10-year mortality after coronary revascularization","volume":"78","author":"Kawashima","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102614581603800_ehab884-B12","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1093\/eurheartj\/ehab280","article-title":"Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Madhavan","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B13","first-page":"hab395","article-title":"Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial)","author":"Romaguera","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B14","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0140-6736(20)32173-5","article-title":"Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial","volume":"396","author":"Jeger","year":"2020","journal-title":"Lancet"},{"key":"2022102614581603800_ehab884-B15","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1093\/eurheartj\/ehz594","article-title":"Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)","volume":"41","author":"Giacoppo","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B16","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1093\/eurheartj\/ehab283","article-title":"The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)","volume":"42","author":"Hildick-Smith","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B17","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1093\/eurheartj\/ehab363","article-title":"Left main coronary disease at the bifurcation: should the pendulum swing back towards the provisional stenting approach?","volume":"42","author":"Jaffer","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.120.046754","article-title":"Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies CTO-arc consensus recommendations","volume":"143","author":"Ybarra","year":"2021","journal-title":"Circulation"},{"key":"2022102614581603800_ehab884-B19","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jacc.2021.05.055","article-title":"Global chronic total occlusion crossing algorithm: JACC state-of-the-art review","volume":"78","author":"Wu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102614581603800_ehab884-B20","doi-asserted-by":"crossref","first-page":"e008239","DOI":"10.1161\/CIRCINTERVENTIONS.119.008239","article-title":"Trends in usage and clinical outcomes of coronary atherectomy: a report from the national cardiovascular data registry CathPCI registry","volume":"13","author":"Beohar","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jcin.2021.04.034","article-title":"Operator volumes and in-hospital outcomes: an analysis of 7,740 rotational atherectomy procedures from the BCIS national database","volume":"14","author":"Kinnaird","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B22","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.jacc.2020.09.603","article-title":"Intravascular lithotripsy for treatment of severely calcified coronary artery disease","volume":"76","author":"Hill","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102614581603800_ehab884-B23","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1093\/eurheartj\/ehab449","article-title":"Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)","volume":"42","author":"Collison","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jcin.2019.09.033","article-title":"Effect of intravascular ultrasound\u2013guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial","volume":"13","author":"Hong","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B25","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/S0140-6736(21)02248-0","article-title":"Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial","volume":"398","author":"Xu","year":"2021","journal-title":"Lancet"},{"key":"2022102614581603800_ehab884-B26","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1093\/eurheartj\/ehaa173","article-title":"Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events","volume":"41","author":"Shishikura","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B27","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jacc.2020.09.547","article-title":"Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque","volume":"76","author":"Stone","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102614581603800_ehab884-B28","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1093\/eurheartj\/ehab433","article-title":"Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT\u2013FFR trial","volume":"42","author":"Kedhi","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B29","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/eurheartj\/ehaa036","article-title":"Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial","volume":"41","author":"Thiele","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B30","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.120.051547","article-title":"Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: SCOPE 2 randomized clinical trial","volume":"142","author":"Tamburino","year":"2020","journal-title":"Circulation"},{"key":"2022102614581603800_ehab884-B31","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s00392-021-01882-3","article-title":"The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes","volume":"110","author":"M\u00f6llmann","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2022102614581603800_ehab884-B32","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/eurheartj\/ehab213","article-title":"A randomized evaluation of the TriGuard\u2122 HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve Implan Tation: the REFLECT I trial","volume":"42","author":"Lansky","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcin.2020.11.011","article-title":"Randomized evaluation of TriGuard 3 cerebral embolic protection after transcatheter aortic valve replacement: REFLECT II","volume":"14","author":"Nazif","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B34","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jcin.2019.12.006","article-title":"Prior balloon valvuloplasty versus direct transcatheter aortic valve replacement: results from the DIRECTAVI trial","volume":"13","author":"Leclercq","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B35","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1093\/eurheartj\/ehab375","article-title":"Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement","volume":"42","author":"J\u00f8rgensen","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B36","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/eurheartj\/ehaa544","article-title":"Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves","volume":"41","author":"Bleiziffer","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B37","first-page":"ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102614581603800_ehab884-B39","article-title":"STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome","author":"Watanabe","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B41","doi-asserted-by":"crossref","first-page":"e010144","DOI":"10.1161\/CIRCINTERVENTIONS.120.010144","article-title":"Primary results of the EVOLVE short DAPT study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent","volume":"14","author":"Kirtane","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B42","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102614581603800_ehab884-B43","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614581603800_ehab884-B44","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"2022102614581603800_ehab884-B45","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"2022102614581603800_ehab884-B46","article-title":"Anti-thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after trans-aortic valve implantation for aortic stenosis\u2014ATLANTIS","volume-title":"American College of Cardiology Virtual Annual Scientific Session (ACC 2021)","author":"Montalescot","year":"2021"},{"key":"2022102614581603800_ehab884-B47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614581603800_ehab884-B48","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614581603800_ehab884-B49","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin k antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102614581603800_ehab884-B50","doi-asserted-by":"crossref","first-page":"e009603","DOI":"10.1161\/JAHA.118.009603","article-title":"Diagnostic performance of in-procedure angiography-derived quantitative flow reserve compared to pressure-derived fractional flow reserve: the FAVOR II Europe-Japan study","volume":"7","author":"Westra","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022102614581603800_ehab884-B51","doi-asserted-by":"crossref","first-page":"e001326","DOI":"10.1136\/openhrt-2020-001326","article-title":"Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study","volume":"7","author":"Garot","year":"2020","journal-title":"Open Heart"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/5\/377\/46646024\/ehab884.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/5\/377\/46646024\/ehab884.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T15:40:48Z","timestamp":1666798848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/5\/377\/6491389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,1,3]]},"published-print":{"date-parts":[[2022,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab884","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"type":"print","value":"0195-668X"},{"type":"electronic","value":"1522-9645"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2022,1,3]]}}}